Biogen has made an unsolicited offer to acquire its partner Sage Therapeutics following a year of significant challenges for the latter. The deal, which values Sage at $7.22 per share, represents ...

Sage Therapeutics (SAGE) said Biogen (BIIB) has made an unsolicited offer to acquire the rest of SAGE shares. Biogen currently owns a 10.2% stake in Sage Therapeutics; SAGE board members will ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Sage Therapeutics and Biogen's antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a falloff in efficacy over time has raised concerns about the commercial potential ...

Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, noting that the impact of Biogen’s ...

BofA resumed coverage of Sage Therapeutics (SAGE) with an Underperform rating and $5 price target. The impact of Biogen’s (BIIB) unsolicited takeover has now passed, and in the absence of clear ...

Sage Therapeutics and partner Biogen equally shares profits and losses for the commercialization of Zurzuvae in the United States. In ex-U.S. markets, Biogen records product sales (excluding Japan ...

As the Cambridge drugmaker contemplates its future, the biotech’s chief medical officer has become the latest executive to exit the company. As Sage Therapeutics Inc. contemplates its path ...

Farmer covers the Healthcare sector, focusing on stocks such as SAGE Therapeutics, Kura Oncology, and Biomea Fusion. In addition to Scotiabank, Biogen also received a Buy from Canaccord Genuity ...

Biogen Inc. plans to move its headquarters into a 16-story Kendall Square tower to be developed by MIT and BioMed Realty ...